UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Role of Serum Uric Acid and Ferritin in the Development and Progression of NAFLD

International Journal of Molecular Sciences, 2016-04, Vol.17 (4), p.548-548

2016

Volltextzugriff (PDF)

Progression of carotid vascular damage and cardiovascular events in non-alcoholic fatty liver disease patients compared to the general population during 10 years of follow-up

Atherosclerosis, 2016-03, Vol.246, p.208-213

2016

Volltextzugriff (PDF)

Epicardial Adipose Tissue (EAT) Thickness Is Associated with Cardiovascular and Liver Damage in Nonalcoholic Fatty Liver Disease

PloS one, 2016-09, Vol.11 (9), p.e0162473-e0162473

2016

Volltextzugriff (PDF)

Vascular Damage in Patients with Nonalcoholic Fatty Liver Disease: Possible Role of Iron and Ferritin

International journal of molecular sciences, 2016-05, Vol.17 (5), p.675-675

2016

Volltextzugriff (PDF)

Cardiovascular risk after orthotopic liver transplantation, a review of the literature and preliminary results of a prospective study

World journal of gastroenterology : WJG, 2016-10, Vol.22 (40), p.8869-8882

2016

Volltextzugriff (PDF)

Cardiovascular involvement after liver transplantation: role of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis

Exploration of medicine, 2021-02, Vol.2 (1), p.20-38

2021

Volltextzugriff (PDF)

Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity

Clinical gastroenterology and hepatology, 2017-10, Vol.15 (10), p.1604-1611.e1

2017

Volltextzugriff (PDF)

Unusual presentation in a case of primary hyperparathyroidism

Journal of research in medical sciences, 2011-08, Vol.16 (8), p.1078-1081

2011

Volltextzugriff (PDF)

Are non-invasive tests of fibrosis effective in patients with metabolic associated fatty liver disease? Comparative study between liver biopsy and non-invasive scores or fibroscan

Journal of hepatology, 2023-06, Vol.78, p.S722-S723

2023

Volltextzugriff (PDF)

SAT-506 - Are non-invasive tests of fibrosis effective in patients with metabolic associated fatty liver disease? Comparative study between liver biopsy and non-invasive scores or fibroscan

Journal of hepatology, 2023-06, Vol.78, p.S722-S723

2023

Volltextzugriff (PDF)

Liver fibrosis by FibroScan® independently of established cardiovascular risk parameters associates with macrovascular and microvascular complications in patients with type 2 diabetes

Liver international, 2020-02, Vol.40 (2), p.347-354

2020

Volltextzugriff (PDF)

FRI-248-YI The impact of baseline sarcopenia, over time, on liver and cardiovascular damage in patients with metabolic-dysfunction associated steatotic liver disease (MASLD): a prospective study

Journal of hepatology, 2024-06, Vol.80, p.S482-S482

2024

Volltextzugriff (PDF)

FRI-226 The impact of light to moderate alcohol consumption on liver and cardiovascular damage in metabolic-dysfunction associated steatotic liver disease

Journal of hepatology, 2024-06, Vol.80, p.S474-S474

2024

Volltextzugriff (PDF)

FRI-207-YI Sarcopenia in metabolic-dysfunction associated steatotic liver disease (MASLD): unraveling its role in cardiovascular damage

Journal of hepatology, 2024-06, Vol.80, p.S466-S467

2024

Volltextzugriff (PDF)

PCSK9 deficiency results in increased ectopic fat accumulation in experimental models and in humans

European journal of preventive cardiology, 2017-11, Vol.24 (17), p.1870-1877

2017

Volltextzugriff (PDF)

SGLT2 inhibitors improve hepatic fibrosis assessed by Fibroscan in NAFLD patients with type 2 diabetes: a five-year follow-up study

Journal of hepatology, 2023-06, Vol.78, p.S814-S815

2023

Volltextzugriff (PDF)

FRI-474 - SGLT2 inhibitors improve hepatic fibrosis assessed by Fibroscan in NAFLD patients with type 2 diabetes: a five-year follow-up study

Journal of hepatology, 2023-06, Vol.78, p.S814-S815

2023

Volltextzugriff (PDF)

Comparison of the severity of metabolic, liver and cardiovascular damage in NAFLD patients attending the hepatology clinic over the last three decades

Digestive and liver disease, 2024-01, Vol.56 (1), p.144-151

2024

Volltextzugriff (PDF)

Comparison of hepatic and cardiovascular damage between HIV patients with steatosis and NAFLD: role of metabolic alterations and low visceral adiposity

Journal of hepatology, 2022-07, Vol.77, p.S167

2022

Volltextzugriff (PDF)

The rs599839 A>G Variant Disentangles Cardiovascular Risk and Hepatocellular Carcinoma in NAFLD Patients

Cancers, 2021-04, Vol.13 (8), p.1783

2021

Volltextzugriff (PDF)

Reply to Comment: Is there any place for SGLT2-inhibitors in post-liver transplantation patients?

Digestive and liver disease, 2020-04, Vol.52 (4), p.470-471

2020

Volltextzugriff (PDF)

FibroScan Identifies Patients With Nonalcoholic Fatty Liver Disease and Cardiovascular Damage

Clinical gastroenterology and hepatology, 2020-02, Vol.18 (2), p.517-519

2020

Volltextzugriff (PDF)

FRI433 - Procoagulant imbalance in patients with non-cirrhotic chronic hepatitis C (CHC) improves six months after eradication with direct-acting antiviral agents (DAAs) and likely correlates with liver fibrosis

Journal of hepatology, 2020-08, Vol.73, p.S612-S612

2020

Volltextzugriff (PDF)

Procoagulant imbalance in patients with non-cirrhotic chronic hepatitis C (CHC) improves six months after eradication with direct-acting antiviral agents (DAAs) and likely correlates with liver fibrosis

Journal of hepatology, 2020-08, Vol.73, p.S612

2020

Volltextzugriff (PDF)

Procoagulant imbalance influences cardiovascular and liver damage in chronic hepatitis C independently of steatosis

Liver international, 2019-12, Vol.39 (12), p.2309-2316

2019

Volltextzugriff (PDF)

1 – 25 von 90

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(81)
Mit Volltextzugriff
(74)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Role of Serum Uric Acid and Ferritin in the Development and Progression of NAFLD

Progression of carotid vascular damage and cardiovascular events in non-alcoholic fatty liver disease patients compared to the general population during 10 years of follow-up

Epicardial Adipose Tissue (EAT) Thickness Is Associated with Cardiovascular and Liver Damage in Nonalcoholic Fatty Liver Disease

Vascular Damage in Patients with Nonalcoholic Fatty Liver Disease: Possible Role of Iron and Ferritin

Cardiovascular risk after orthotopic liver transplantation, a review of the literature and preliminary results of a prospective study

Cardiovascular involvement after liver transplantation: role of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis

Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity

Unusual presentation in a case of primary hyperparathyroidism

Are non-invasive tests of fibrosis effective in patients with metabolic associated fatty liver disease? Comparative study between liver biopsy and non-invasive scores or fibroscan

SAT-506 - Are non-invasive tests of fibrosis effective in patients with metabolic associated fatty liver disease? Comparative study between liver biopsy and non-invasive scores or fibroscan

Liver fibrosis by FibroScan® independently of established cardiovascular risk parameters associates with macrovascular and microvascular complications in patients with type 2 diabetes

FRI-248-YI The impact of baseline sarcopenia, over time, on liver and cardiovascular damage in patients with metabolic-dysfunction associated steatotic liver disease (MASLD): a prospective study

FRI-226 The impact of light to moderate alcohol consumption on liver and cardiovascular damage in metabolic-dysfunction associated steatotic liver disease

FRI-207-YI Sarcopenia in metabolic-dysfunction associated steatotic liver disease (MASLD): unraveling its role in cardiovascular damage

PCSK9 deficiency results in increased ectopic fat accumulation in experimental models and in humans

SGLT2 inhibitors improve hepatic fibrosis assessed by Fibroscan in NAFLD patients with type 2 diabetes: a five-year follow-up study

FRI-474 - SGLT2 inhibitors improve hepatic fibrosis assessed by Fibroscan in NAFLD patients with type 2 diabetes: a five-year follow-up study

Comparison of the severity of metabolic, liver and cardiovascular damage in NAFLD patients attending the hepatology clinic over the last three decades

Comparison of hepatic and cardiovascular damage between HIV patients with steatosis and NAFLD: role of metabolic alterations and low visceral adiposity

The rs599839 A>G Variant Disentangles Cardiovascular Risk and Hepatocellular Carcinoma in NAFLD Patients

Reply to Comment: Is there any place for SGLT2-inhibitors in post-liver transplantation patients?

FibroScan Identifies Patients With Nonalcoholic Fatty Liver Disease and Cardiovascular Damage

FRI433 - Procoagulant imbalance in patients with non-cirrhotic chronic hepatitis C (CHC) improves six months after eradication with direct-acting antiviral agents (DAAs) and likely correlates with liver fibrosis

Procoagulant imbalance in patients with non-cirrhotic chronic hepatitis C (CHC) improves six months after eradication with direct-acting antiviral agents (DAAs) and likely correlates with liver fibrosis

Procoagulant imbalance influences cardiovascular and liver damage in chronic hepatitis C independently of steatosis

Suchergebnisse filtern